Health & Medication Blog
Evidence-based guides, comparisons, and practical advice for GLP-1 medications, TRT, HRT, mental health, and more. Updated regularly with the latest research, FDA news, and pricing.
Icotyde vs Skyrizi vs Otezla: Comparing Psoriasis Treatments in 2026
The FDA approval of Icotyde in March 2026 marks a turning point in psoriasis treatment, offering the first oral IL-23 receptor antagonist that competes with injectable biologics. This guide helps patients and providers navigate switching decisions between Icotyde, Skyrizi, and Otezla.
Switching from Injectable to Oral Psoriasis Treatment: A 2026 Guide
Many psoriasis patients are seeking relief from frequent injections. With new oral treatments like Icotyde now available, switching from injectable biologics to pills is becoming a realistic and appealing option in 2026.
Icotyde (Icotrokinra): The First Oral Psoriasis Pill — Complete Guide (2026)
Icotyde (icotrokinra) is the first oral IL-23 receptor antagonist, approved by the FDA on March 17, 2026. Developed by Johnson & Johnson and Protagonist Therapeutics, it offers moderate-to-severe plaque psoriasis patients a once-daily pill alternative to injectable biologics.
Planning a medication switch?
Use our free calculator to get a personalized switching plan, dose mapping, and cost comparison.
Try the MedSwitcher CalculatorResearch without missing the move
Get the important GLP-1 updates, not more noise
We’ll send the high-signal stuff only: pricing changes, shortages, and new switch guidance worth acting on.
- Price and access changes
- New medication comparisons
- Actionable switch guidance
No spam. Unsubscribe anytime. We never share your email.